Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Pediatric Nephrology
Published in: Pediatric Nephrology 1/2012

01-01-2012 | Educational Review

Hepcidin in anemia of chronic kidney disease: review for the pediatric nephrologist

Authors: Meredith A. Atkinson, Colin T. White

Published in: Pediatric Nephrology | Issue 1/2012

Login to get access

Abstract

Anemia coincident with hyporesponsiveness to erythropoiesis-stimulating agents is an ongoing and prevalent problem in children with chronic kidney disease (CKD). The recently identified iron-regulatory protein hepcidin appears likely to play a significant role in this problem. Hepcidin up-regulation in the setting of CKD, with subsequent increased serum levels, results in impaired iron absorption from the intestine and decreased iron release from body storage sites. Ultimately, in the setting of such elevated levels, a state of functional iron deficiency may develop and lead to anemia due to iron-restricted erythropoiesis. Elevated hepcidin levels are expected in the face of decreased glomerular filtration rate and inflammation. Based on current evidence, it seems likely that hepcidin represents a potentially modifiable mediator of anemia of CKD and is thus a potential target for future anemia therapy. Currently, increased removal via intensified dialysis and-/or blockade of the inflammatory pathway appear to be two viable generic strategies for reducing hepcidin levels. Goals of directly manipulating the hepcidin pathway should offer the pediatric clinician new options for treating the complex anemia associated with CKD.
Literature
1.
Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW (1987) Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 316(2):73–78PubMedCrossRef
2.
Eschbach JW, Adamson JW (1999) Iron overload in renal failure patients: changes since the introduction of erythropoietin therapy. Kidney Int Suppl 69:S35–S43PubMedCrossRef
3.
Guyton AC, Hall JE (2000) Textbook of medical physiology, 10th edn. Saunders, Philadelphia
4.
Geary DF, Schaefer F (2008) Comprehensive pediatric nephrology. Mosby/Elsevier, Philadelphia
5.
Atkinson MA, Martz K, Warady BA, Neu AM (2010) Risk for anemia in pediatric chronic kidney disease patients: a report of NAPRTCS. Pediatr Nephrol 25(9):1699–1706PubMedCrossRef
6.
Bamgbola OF, Kaskel FJ, Coco M (2009) Analyses of age, gender and other risk factors of erythropoietin resistance in pediatric and adult dialysis cohorts. Pediatr Nephrol 24(3):571–579PubMedCrossRef
7.
Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R, Investigators TREAT (2009) A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361(21):2019–2032PubMedCrossRef
8.
Unger EF, Thompson AM, Blank MJ, Temple R (2010) Erythropoiesis-stimulating agents–time for a reevaluation. N Engl J Med 362(3):189–192PubMedCrossRef
9.
Gillespie RS, Wolf FM (2004) Intravenous iron therapy in pediatric hemodialysis patients: a meta-analysis. Pediatr Nephrol 19(6):662–666PubMedCrossRef
10.
National Kidney Foundation (2006) KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 47(5S3):S11–S145
11.
Handelman GJ, Levin NW (2009) Iron and anemia in human biology: a review of mechanisms. Heart Fail Rev 13(4):393–404CrossRef
12.
Goodnough LT, Nemeth E, Ganz T (2010) Detection, evaluation, and management of iron-restricted erythropoiesis. Blood 116(23):4754–4761PubMedCrossRef
13.
Roy CN, Andrews NC (2005) Anemia of inflammation: the hepcidin link. Curr Opin Hematol 12(2):107–111PubMedCrossRef
14.
Weiss G, Goodnough LT (2005) Anemia of chronic disease. N Engl J Med 52(10):1011–1023CrossRef
15.
Thomas C, Thomas L (2005) Anemia of chronic disease: pathophysiology and laboratory diagnosis. Lab Hematol 1(1):14–23CrossRef
16.
Malyszko J, Mysliwiec M (2007) Hepcidin in anemia and inflammation in chronic kidney disease. Kidney Blood Press Res 30(1):15–30PubMedCrossRef
17.
Kalantar-Zadeh K, Lee GH (2006) The fascinating but deceptive ferritin: to measure it or not to measure it in chronic kidney disease? Clin J Am Soc Nephrol Suppl 1:S9–S18
18.
Babitt JL, Lin HY (2010) Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD. Am J Kidney Dis 55(4):726–741PubMedCrossRef
19.
20.
Braun J, Lindner K, Schreiber M, Heidler RA, Horl WH (1997) Percentage of hypochromic red blood cells as predictor of erythropoietic and iron response after i.v. iron supplementation in maintenance haemodialysis patients. Nephrol Dial Transplant 12(6):1173–1181PubMedCrossRef
21.
National Kidney Foundation (2007) KDOQI clinical practice cuideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 50(3):471–530CrossRef
22.
23.
Fishbane S (2008) Upper limit of serum ferritin: misinterpretation of the 2006 KDOQI anemia guidelines. Semin Dial 21(3):217–220PubMedCrossRef
24.
Franchini M, Montagnana M, Lippi G (2010) Hepcidin and iron metabolism: From laboratory to clinical implications. Clin Chim Acta 411(21–22):1565–1569PubMedCrossRef
25.
Zaritsky J, Young B, Wang HJ, Westerman M, Olbina G, Nemeth E, Ganz T, Rivera S, Nissenson AR, Salusky IB (2009) Hepcidin–a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol 4(6):1051–1056PubMedCrossRef
26.
Ashby DR, Gale DP, Busbridge M, Murphy KG, Duncan ND, Cairns TD, Taube DH, Bloom SR, Tam FW, Chapman RS, Maxwell PH, Choi P (2009) Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int 75(9):976–981PubMedCrossRef
27.
Swinkels DW, Wetzels JF (2008) Hepcidin: a new tool in the management of anaemia in patients with chronic kidney disease? Nephrol Dial Transplant 23(8):2450–2453PubMedCrossRef
28.
Kemna EH, Tjalsma H, Willems HL, Swinkels DW (2008) Hepcidin: from discovery to differential diagnosis. Haematologica 93(1):90–97PubMedCrossRef
29.
Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M (2008) Immunoassay for human serum hepcidin. Blood 112(10):4292–4297PubMedCrossRef
30.
31.
Roy CN, Mak HH, Akpan I, Losyev G, Zurakowski D, Andrews NC (2007) Hepcidin antimicrobial peptide transgenic mice exhibit features of the anemia of inflammation. Blood 109(9):4038–4044PubMedCrossRef
32.
Malyszko J, Malyszko JS, Pawlak K, Mysliwiec M (2006) Hepcidin, iron status, and renal function in chronic renal failure, kidney transplantation, and hemodialysis. Am J Hematol 81(11):832–837PubMedCrossRef
33.
Malyszko J, Malyszko JS, Kozminski P, Mysliwiec M (2009) Type of renal replacement therapy and residual renal function may affect prohepcidin and hepcidin. Ren Fail 31(10):876–883PubMedCrossRef
34.
35.
Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, Ganz T (2004) IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 113(9):1271–1276PubMed
36.
Balakrishnan VS, Guo D, Rao M, Jaber BL, Tighiouart H, Freeman RL, Huang C, King AJ, Pereira BJ, HEMO Study Group (2004) Cytokine gene polymorphisms in hemodialysis patients: association with comorbidity, functionality, and serum albumin. Kidney Int 65(4):1449–1460PubMedCrossRef
37.
Poole S, Bird TA, Selkirk S, Gaines-Das RE, Choudry Y, Stephenson SL, Kenny AJ, Saklatvaa J (1990) Fate of injected interleukin 1 in rats: sequestration and degradation in the kidney. Cytokine 2(6):416–422PubMedCrossRef
38.
Bemelmans MH, Gouma DJ, Buurman WA (1993) Influence of nephrectomy on tumor necrosis factor clearance in a murine model. J Immunol 150(5):2007–2017PubMed
39.
Zwolinska D, Medynska A, Szprynger K, Szczepanska M (2000) Serum concentration of IL-2, IL-6, TNF-alpha and their soluble receptors in children on maintenance hemodialysis. Nephron 86(4):441–446PubMedCrossRef
40.
Goldstein SL, Leung JC, Silverstein DM (2006) Pro- and anti-inflammatory cytokines in chronic pediatric dialysis patients: effect of aspirin. Clin J Am Soc Nephrol 1(5):979–986PubMedCrossRef
41.
Pecoits-Filho R, Sylvestre LC, Stenvinkel P (2005) Chronic kidney disease and inflammation in pediatric patients: from bench to playground. Pediatr Nephrol 20(6):714–720PubMedCrossRef
42.
Sylvestre LC, Fonseca KP, Stinghen AE, Pereira AM, Meneses RP, Pecoits-Filho R (2007) The malnutrition and inflammation axis in pediatric patients with chronic kidney disease. Pediatr Nephrol 22(6):864–873PubMedCrossRef
43.
Oberg BP, McMenamin E, Lucas FL, McMonagle E, Morrow J, Ikizler TA, Himmelfarb J (2004) Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 65(3):1009–1016PubMedCrossRef
44.
Kalantar-Zadeh K, McAllister CJ, Lehn RS, Lee GH, Nissenson AR, Kopple JD (2003) Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. Am J Kidney Dis 42(4):761–773PubMedCrossRef
45.
46.
Tessitore N, Girelli D, Campostrini N, Bedogna V, Pietro Solero G, Castagna A, Melilli E, Mantovani W, De Matteis G, Olivieri O, Poli A, Lupo A (2010) Hepcidin is not useful as a biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents. Nephrol Dial Transplant 25(12):3996–4002PubMedCrossRef
47.
Weiss G, Theurl I, Eder S, Koppelstaetter C, Kurz K, Sonnweber T, Kobold U, Mayer G (2009) Serum hepcidin concentration in chronic haemodialysis patients: associations and effects of dialysis, iron and erythropoietin therapy. Eur J Clin Invest 39(10):883–890PubMedCrossRef
48.
Zaritsky J, Young B, Gales B, Wang HJ, Rastogi A, Westerman M, Nemeth E, Ganz T, Salusky IB (2010) Reduction of Serum Hepcidin by Hemodialysis in Pediatric and Adult Patients. Clin J Am Soc Nephrol 5(6):1010–1014PubMedCrossRef
49.
Ganz T, Nemeth E (2009) Iron sequestration and anemia of inflammation. Semin Hematol 46(4):387–393PubMedCrossRef
50.
Kawabata H, Tomosugi N, Kanda J, Tanaka Y, Yoshizaki K, Uchiyama T (2007) Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman's disease. Haematologica 92(6):857–858PubMedCrossRef
Metadata
Title
Hepcidin in anemia of chronic kidney disease: review for the pediatric nephrologist
Authors
Meredith A. Atkinson
Colin T. White
Publication date
01-01-2012
Publisher
Springer-Verlag
Published in
Pediatric Nephrology / Issue 1/2012
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-011-1832-y

Other articles of this Issue 1/2012

Pediatric Nephrology 1/2012 Go to the issue

Editorial

New Year's message from the editors

Original Article

Manifestation of atypical hemolytic uremic syndrome caused by novel mutations in MCP

Original Article

Clinical presentation and metabolic features of overt and occult urolithiasis

Original Article

Longitudinal study of bone mineral density in children with idiopathic hypercalciuria

Erratum

Erratum to: Hypertension in infancy: diagnosis, management and outcome

Review

Hypertension in infancy: diagnosis, management and outcome